Oral composition

The oral composition of Senna plants with Bacillus, Enterococcus, and Clostridium bacteria, along with cellulose and lysine, addresses the lack of intestinal cell activation in conventional laxatives, offering enhanced intestinal regulation and immune support.

JP2024165973APending Publication Date: 2024-11-28TOYO SHINYAKU KK
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023082609
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-18
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Conventional techniques using Senna plants and bacteria primarily function as laxatives and do not adequately activate intestinal cells, neglecting the potential for intestinal regulation and immune activation.

Method used

An oral composition comprising Senna plants combined with specific bacteria from the Bacillus, Enterococcus, and Clostridium genera, along with cellulose and lysine, to enhance intestinal cell activation.

Benefits of technology

The composition effectively activates intestinal cells, improving intestinal immunity and potentially preventing conditions like inflammation and impaired glucose tolerance associated with obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024165973000001_ABST
    Figure 2024165973000001_ABST
Patent Text Reader

Abstract

To provide an agent that is effective and safe for consumption, capable of activating intestinal cells.SOLUTION: The present invention provides an oral composition containing the following (A) and (B). Preferably, the oral composition further contains the following (C), and more preferably, the following (D). (A) Cassia plants. (B) At least one bacterium selected from Bacillus, Enterococcus, and Clostridium species. (C) Cellulose. (D) Lysine.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to oral compositions containing the plant of the genus Senna. [Background technology]

[0002] Conventionally, Senna plants such as Senna are known to contain laxative components such as sennosides. Sennosides are known to be metabolized by intestinal bacteria, for example, metabolized to senidin by β-glucosidase of Bifidobacterium genus (bifidobacteria), and further metabolized to the active substance rheinanthrone by reductase of Peptostreptococcus genus. In addition, as an oral preparation utilizing such metabolic action, an oral preparation that combines Senna plants with bifidobacteria and the like is known (for example, Patent Document 1).

[0003] On the other hand, intestinal epithelial cells not only absorb nutrients and water, but also form robust tight junctions and function as a physical barrier against foreign microorganisms, and also play a role in host defense through the formation of a thick mucin layer and the secretion of antimicrobial peptides. Therefore, it is expected that activating intestinal epithelial cells will regulate intestinal immunity, leading to intestinal regulation and activation of intestinal immunity. In addition, in recent years, the relationship between immune responses in intestinal epithelial cells and obesity has become known. It is known that a high-fat diet causes inflammation in intestinal epithelial cells, which leads to the deterioration of obesity pathology such as glucose intolerance and insulin resistance (Non-Patent Document 1). Therefore, it is expected that activating intestinal epithelial cells will have the effect of preventing and improving pathology such as inflammation and glucose intolerance caused by obesity.

[0004] However, conventional techniques using a combination of Senna plants and bacteria, such as those described in Patent Document 1, have been used solely as laxatives to promote the excretion of waste materials, and their ability to directly act on intestinal cells, such as intestinal epithelial cells, to activate intestinal cells has not been fully explored. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2012-158561 A [Non-patent literature]

[0006] [Non-Patent Document 1] Journal of the Japanese Diabetes Association, Vol. 61, No. 3, p. 100-103, https: / / www.jstage.jst.go.jp / article / tonyobyo / 61 / 3 / 61_100 / _pdf Summary of the Invention [Problem to be solved by the invention]

[0007] The present invention has been made in response to such conventional problems, and an object of the present invention is to provide an oral composition capable of activating intestinal cells. [Means for solving the problem]

[0008] The present invention provides the following [1] to [3]. [1] An oral composition comprising the following (A) and (B): (A) Senna plant (B) one or more bacteria selected from the genus Bacillus, the genus Enterococcus, and the genus Clostridium [2] An oral composition comprising the following (A), (B) and (C): (A) Senna plant (B) one or more bacteria selected from the genus Bacillus, the genus Enterococcus, and the genus Clostridium (C) Cellulose [3] An oral composition comprising the following (A), (B), (C) and (D): (A) Senna plant (B) one or more bacteria selected from the genus Bacillus, the genus Enterococcus, and the genus Clostridium (C) Cellulose (D) Lysine Effect of the Invention

[0009] The present invention can provide an effective and safe ingestible agent capable of activating intestinal cells. [Brief description of the drawings]

[0010] [Figure 1] FIG. 1 shows the Caco-2 cell activating activity in the examples and comparative examples. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The following describes preferred embodiments of the present invention. In the following description, the term "oral composition" refers to all of the oral compositions [1] to [3].

[0012] (A) Senna plant The genus Senna corresponds to the Latin name Cassia, and is sometimes called Senna in English. In Japan, the genus Senna is sometimes called Cassia japonica. (A) Specific examples of plants of the genus Senna include senna (Cassia angustifolia, sometimes called Senna alexandrina), candle bush (Cassia alata, sometimes called golden candle), senna (Cassia coluteoides), senna flower (Cassia corymbosa Lam.), senna palmatum (Cassia didymobotrya), honey locust (Cassia Fistula), senna javanica, Cassia mimosoides ssp. Nomame, Cassia obtusifolia Linn., Cassia occidentalis L., Cassia siamea Lam., senna sophera Linn., and senna (Cassia Cassia surattensis, Cassia timorensis, etc. Among them, it is more preferable to use at least one selected from senna and candle bush, which have a high effect of activating intestinal cells, and it is most preferable to use a combination of senna and candle bush.

[0013] When senna and candle bush are combined, the mass ratio of senna:candle bush (former:latter) is preferably 100:0.1-1,000,000, more preferably 100:1-100,000, and even more preferably 100:10-1,000, in order to enhance the effect of activating intestinal cells.

[0014] The part of the (A) Senna plant may be the whole plant or a fraction selected from the stem, leaflet, petiole, leaf axis, fruit and flower. Any part of the (A) Senna plant may be used, but the part to be used is preferably selected from the stem, fruit and flower, more preferably selected from the stem, leaf and fruit, and particularly preferably the stem or leaf. For example, it is preferable to use the stem of senna. For candle bush, it is preferable to use the leaf. Here, the leaf includes the leaflet, petiole and leaf axis.

[0015] As the (A) Senna plant used in the present invention, various processed products obtained from Senna plants can be used. The processed products include, but are not limited to, fermented products of the plant body; crushed and dried powdered plant body (crushed powder); squeezed juice of the plant body or dried powdered juice thereof (squeezed juice powder); extracts of the plant body and dried powdered products (extract powder (sometimes referred to as "extract powder")), etc. When powdering the squeezed juice or extract, an excipient can be used as necessary. In the following, the extract is referred to as "extract", and the extract dried and powdered is referred to as extract powder. Unless otherwise specified in this specification, "extract" includes all extracts regardless of their form, including extract powder.

[0016] As the (A) Senna plant of the present invention, from the viewpoint of particularly excellent effects of the present invention, it is particularly preferable to use an extract or crushed powder of the (A) Senna plant, and it is more preferable to use an extract from the viewpoint of high effect of activating intestinal cells, and it is particularly preferable to use a combination of an extract and a crushed product, and it is more preferable to combine an extract of one kind of Senna plant with a crushed powder of another kind of Senna plant. Here, it is particularly preferable that the extract is an extract powder.

[0017] The extract can be obtained by extracting the target part of the Senna plant (A) with an extraction solvent, either as is or, if necessary, after drying, chopping, crushing, squeezing or boiling. The solvent used for extraction may be cold water, hot water, an organic solvent, or a mixture of water and an organic solvent.

[0018] Examples of the organic solvent include alcohols, including lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, and isopropanol, and polyhydric alcohols such as propylene glycol, 1,3-butylene glycol, and glycerin, ketones such as acetone, esters such as ethyl acetate, chloroform, and hydrocarbons such as pentane, hexane, and heptane, either alone or in combination. Among the above extraction solvents, water, alcohol, or a mixed solvent of water and alcohol is preferred, and alcohol or a mixed solvent of water and alcohol is particularly preferred, lower alcohol or a mixed solvent of water and lower alcohol is particularly preferred, and ethanol or a mixed solvent of water and ethanol is most preferred, from the viewpoint of high effect of activating intestinal cells.

[0019] The extraction temperature is preferably room temperature or higher, for example, from room temperature to about 100°C, and more preferably at a high temperature of about 50 to 80°C.

[0020] For example, the extraction time may be about 1 to 300 minutes, and preferably about 10 to 90 minutes.

[0021] The extract obtained above is a liquid in which the soluble components contained in the Senna plant (A) are dissolved in an extraction solvent. The liquid may be a concentrated liquid or may be a dried product (extract powder). Methods for drying the liquid obtained above to obtain an extract powder include a method for removing the extraction solvent by vacuum distillation or the like, a method for removing the extraction solvent by drying treatment such as vacuum drying or freeze drying, a dry spray or spray drying treatment, etc.

[0022] As for the crushed powder, any method may be used so long as it involves drying and crushing (A) a plant of the genus Senna.

[0023] (A) As the extract or crushed powder of a Senna plant, commercially available products can be used.

[0024] In view of its high effect of activating intestinal cells, the (A) Senna plant is preferably contained in the daily intake amount of the oral composition of the present invention in an amount of 1 mg to 10,000 mg, more preferably 5 mg to 5,000 mg, and even more preferably 10 mg to 2,000 mg.

[0025] In view of its high effect of activating intestinal cells, the Senna plant (A) is contained in an amount of preferably 0.01 to 90 mass%, more preferably 0.1 to 80 mass%, and even more preferably 1 to 70 mass%, of the solid content of the oral composition of the present invention.

[0026] In this specification, the solid content refers to the content in the oral composition when the oral composition is solid, and refers to the total amount of all components excluding the solvent in the oral composition when the oral composition is non-solid. The solvent here includes those used in oral compositions, such as water, oils and fats that are liquid at 25° C., and ethanol. Examples of the solid form include powder, granules, particles, and solid forms. The non-solid form does not correspond to the above-mentioned solid form, and examples of the non-solid form include liquid, fluid, and paste forms, and refers to a form in which a solid component is dispersed or dissolved in a solvent such as water. In this specification, when the composition is in the form of a capsule, the composition refers to the contents of the capsule, and the weight of the capsule itself is not included in the weight of the composition.

[0027] (B) Specific bacteria In the present invention, (B) one or more types of bacteria selected from the genera Bacillus, Enterococcus, and Clostridium (hereinafter, also referred to as "(B) specific bacteria") are used.

[0028] The specific bacteria (B) used in this embodiment are microorganisms that have beneficial effects on the human or animal body. The specific bacteria (B) may be live or dead, but it is preferable to use live bacteria because of their high effect of activating intestinal cells.

[0029] Bacillus bacteria are spore-forming bacteria, and are usually aerobic gram-positive rods. Since they are lactic acid bacteria that form spores, they are also called spore-forming lactic acid bacteria. Suitable Bacillus bacteria include Bacillus coagulans (also called Weizmannia coagulans), Bacillus mesentericus, Bacillus subtilis, Bacillus megaterium, Bacillus cereus var toyoi, Bacillus licheniformis, etc. Among them, one or more selected from Bacillus coagulans and Bacillus subtilis are preferred because they have a high effect of activating intestinal cells, and Bacillus coagulans is particularly preferred.

[0030] Suitable Enterococcus bacteria include Enterococcus faecalis (also called Streptococcus faecalis), Enterococcus faesium (also called Streptococcus faesium), Enterococcus avium, Enterococcus casseliflavus, Enterococcus gallinarum, Enterococcus flavescen, etc. Among them, one or more species selected from Enterococcus faecalis and Enterococcus faesium are preferred because of their high effect of activating intestinal cells, and Enterococcus faecalis is particularly preferred.

[0031] Examples of Clostridium bacteria include Clostridium butyricum, Clostridium acetobutyricum, Clostridium multifermentus, Clostridium bifermentans, Clostridium pasteurianum, Clostridium toanum, Clostridium perfringens, Clostridium tetanomorphum, Clostridium flavum, and Clostridium tertium. These bacteria produce butyric acid and are also called butyric acid bacteria. Among them, Clostridium butyricum is particularly preferred because of its high effect of activating intestinal cells.

[0032] In the present invention, from the viewpoint of high intestinal cell activation effect, it is preferable to use one or more species selected from the genus Enterococcus and the genus Clostridium among the genus Bacillus, Enterococcus, and Clostridium. Also, from the viewpoint of high intestinal cell activation effect, it is preferable to combine two or more species selected from the genus Bacillus, Enterococcus, and Clostridium. In this case, it is preferable to combine the genus Bacillus and the genus Enterococcus, it is also preferable to combine the genus Bacillus and the genus Clostridium, and it is also preferable to combine the genus Enterococcus and the genus Clostridium. In particular, from the viewpoint of high intestinal cell activation effect, it is most preferable to contain all of the genus Bacillus, Enterococcus, and Clostridium.

[0033] When bacteria of the genus Bacillus and bacteria of the genus Enterococcus are combined, the ratio of the numbers of bacteria of the genus Bacillus:Enterococcus (former:latter) is preferably 100:0.1 to 100,000, more preferably 100:1 to 10,000, and even more preferably 100:10 to 1,000, in order to enhance the effect of activating intestinal cells.

[0034] When bacteria of the genus Bacillus and bacteria of the genus Clostridium are combined, the ratio of the numbers of bacteria of the genus Bacillus:Clostridium (former:latter) is preferably 100:0.002-2000, more preferably 100:0.02-200, and even more preferably 100:0.2-20, from the viewpoint of enhancing the effect of activating intestinal cells.

[0035] When bacteria of the genus Enterococcus and bacteria of the genus Clostridium are combined, the ratio of the number of bacteria of the genus Enterococcus:Clostridium (former:latter) is preferably 100:0.002-2000, more preferably 100:0.02-200, and even more preferably 100:0.2-20, from the viewpoint of enhancing the effect of activating intestinal cells.

[0036] In view of the high effect of activating intestinal cells, the specific bacteria (B) is preferably contained in the daily intake amount of the oral composition of the present invention at 10,000 to 1 trillion bacteria, more preferably at 1 million to 100 billion bacteria, and particularly preferably at 10 million to 10 billion bacteria.

[0037] In view of the high effect of activating intestinal cells, the (B) specific bacterium is contained in an amount of preferably 0.01 to 90 mass %, more preferably 0.1 to 50 mass %, and even more preferably 1 to 25 mass %, of the solid content of the oral composition of the present invention.

[0038] In view of the high effect of activating intestinal cells, the (B) specific bacterium is preferably contained in an amount of 0.1 to 100,000 mass% relative to the (A) Senna plant, more preferably 1 to 10,000 mass%, and even more preferably 10 to 1,000 mass%.

[0039] In view of the high effect of activating intestinal cells, the (B) specific bacteria is preferably contained in an amount of 10,000 to 1 trillion, more preferably 1 million to 100 billion, even more preferably 2 million to 50 billion, and particularly preferably 100 million to 10 billion, per gram of the (A) Senna plant.

[0040] (C) Cellulose Cellulose has the molecular formula (C6H 10 O5)n, which is a polysaccharide in which β-glucose is polymerized through a glycosidic bond. The oral composition of the present invention is preferably composed of (C) cellulose, since it can further enhance the effect of activating intestinal cells. In particular, it is preferable that the specific bacterium (B) contains Enterococcus bacteria and is combined with (C) cellulose. It is also preferable to combine two or more species selected from the specific bacterium (B) of the genus Bacillus, Enterococcus, and Clostridium with (C) cellulose, and it is particularly preferable to combine the specific bacterium (B) of the genus Bacillus, Enterococcus, and Clostridium with (C) cellulose, since it has a high effect of activating intestinal cells.

[0041] The cellulose (C) is preferably powdered cellulose or crystalline cellulose, and is particularly preferably powdered cellulose because of its high effect of activating intestinal cells. Generally available cellulose includes ordinary cellulose in powder form (hereinafter referred to as "powdered cellulose"), such as cellulose floc, and ordinary cellulose in crystalline form (hereinafter referred to as "crystalline cellulose").

[0042] Powdered cellulose is α-cellulose obtained as pulp from fibrous plants, which is treated, refined, and mechanically pulverized. For example, it corresponds to the powdered cellulose described in the 15th Revised Japanese Pharmacopoeia Commentary (published by Hirokawa Shoten). The average degree of polymerization of the powdered cellulose is preferably greater than 440. This value can be measured according to the reduced specific viscosity method using a copper ethylenediamine solution described in the verification test (3) in the 15th Revised Japanese Pharmacopoeia Commentary (published by Hirokawa Shoten). Examples of the powdered cellulose include the KC Floc series of Nippon Paper Industries Co., Ltd., such as KC-Floc W-50, KC-Floc W-100(G), KC-Floc W-200(G), KC-Floc W-250, KC-Floc W-300G, and KC-Floc W-400G. The average degree of polymerization of cellulose is preferably 1500 or less, more preferably 1000 or less.

[0043] Crystalline cellulose is a product obtained by partially depolymerizing α-cellulose obtained as pulp from fibrous plants with an acid and purifying it. For example, it corresponds to the crystalline cellulose described in the 15th Revised Japanese Pharmacopoeia Commentary (published by Hirokawa Shoten). The average degree of polymerization of crystalline cellulose is preferably 350 or less. This value can be measured according to the reduced specific viscosity method using a copper ethylenediamine solution described in the 15th Revised Japanese Pharmacopoeia Commentary (published by Hirokawa Shoten), confirmation test for crystalline cellulose (3). As the crystalline cellulose, for example, the CEOLUS ST series by Asahi Kasei Corporation can be mentioned.

[0044] The average particle size of the cellulose is preferably 100 μm or less, more preferably 70 μm or less, and particularly preferably 50 μm or less. The average particle size in this specification refers to the volume average particle size measured by a laser diffraction particle size distribution measuring device.

[0045] In view of its high effect of activating intestinal cells, (C) cellulose is contained in the daily intake amount of the oral composition of the present invention in an amount of preferably 1 mg to 10,000 mg, more preferably 5 mg to 5,000 mg, and even more preferably 10 mg to 2,000 mg.

[0046] In view of its high effect of activating intestinal cells, (C) cellulose is contained in an amount of preferably 0.01 to 90 mass %, more preferably 0.1 to 50 mass %, and even more preferably 1 to 25 mass %, of the solid content of the oral composition of the present invention.

[0047] In view of the high effect of activating intestinal cells, (C) cellulose is preferably contained in an amount of 0.1 to 100,000 mass% relative to (A) the Senna plant, more preferably 1 to 10,000 mass%, and even more preferably 10 to 1,000 mass%.

[0048] In view of the high effect of activating intestinal cells, (C) cellulose is contained in an amount of preferably 0.1 to 100,000 mass%, more preferably 1 to 10,000 mass%, even more preferably 5 to 5,000 mass%, and particularly preferably 10 to 1,000 mass%, relative to (B) specific bacteria.

[0049] In view of the high effect of activating intestinal cells, the (B) specific bacteria is preferably contained in an amount of 10,000 to 1 trillion per gram of (C) cellulose, more preferably 1 million to 100 billion per gram, even more preferably 2 million to 50 billion per gram, and particularly preferably 100 million to 10 billion per gram.

[0050] (D) Lysine Lysine is a basic amino acid and is also called lysine. The oral composition of the present invention is preferably composed of (D) lysine, since it can further enhance the effect of activating intestinal cells. In particular, it is preferable to combine (D) lysine with (C) cellulose, since it has a high effect of activating intestinal cells. It is also preferable to use (D) lysine in combination with (B) specific bacteria, which is a combination of bacteria from multiple genera, since it has a high effect of activating intestinal cells. In particular, it is also preferable to combine (D) lysine with two or more species selected from the genus Bacillus, Enterococcus, and Clostridium as the specific bacteria (B), and in particular, it is preferable to combine (D) lysine with the genus Bacillus, Enterococcus, and Clostridium bacteria, since it has a high effect of activating intestinal cells.

[0051] (D) Lysine (D) used in the present invention may be obtained by hydrolysis of natural proteins derived from animals or plants, or may be obtained by fermentation or chemical synthesis. (D) Lysine exists as optical isomers in the D-form and L-form, but for use in the present invention, the L-form, which is a component of biological proteins, is preferable. (D) Lysine may be used in the form of various salts. As for (D) Lysine, salts with acids are mainly used because these amino acids are basic. The acid may be either an inorganic acid or an organic acid. Examples of inorganic acids include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, etc. Examples of organic acids include formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citric acid, glutamic acid, aspartic acid, gamma-linolenic acid, tocopherol monosuccinate, tocopherol phosphate, ascorbic acid, ascorbic phosphate, tocopherol ascorbyl phosphate, thioctic acid, N-acetylcysteine, N,N'-diacetylcysteine, and lipoic acid.

[0052] In the oral composition of the present invention, (D) lysine is preferably contained as an amino acid alone or a salt thereof rather than in the form of a peptide or a protein, since this has a high effect of activating intestinal cells. It is particularly preferred that (D) lysine is contained as a salt, and particularly preferably lysine hydrochloride.

[0053] In view of its high effect of activating intestinal cells, (D) lysine is contained in the daily intake amount of the oral composition of the present invention in an amount of preferably 1 mg to 10,000 mg, more preferably 5 mg to 5,000 mg, and even more preferably 10 mg to 2,000 mg.

[0054] In view of its high effect of activating intestinal cells, (D) lysine is contained in an amount of preferably 0.01 to 90 mass %, more preferably 0.1 to 50 mass %, and even more preferably 1 to 25 mass %, of the solid content of the oral composition of the present invention.

[0055] In view of its high effect of activating intestinal cells, (D) lysine is preferably contained in an amount of 0.1 to 100,000 mass% relative to (A) the Senna plant, more preferably 1 to 10,000 mass%, and even more preferably 10 to 1,000 mass%.

[0056] In view of its high effect of activating intestinal cells, (D) lysine is preferably contained in an amount of 0.1 to 100,000 mass%, more preferably 1 to 10,000 mass%, even more preferably 5 to 5,000 mass%, and particularly preferably 10 to 1,000 mass%, relative to (B) specific bacteria.

[0057] In view of the high effect of activating intestinal cells, the (B) specific bacteria is preferably contained in an amount of 10,000 to 1 trillion per gram of (D) lysine, more preferably 1 million to 100 billion, even more preferably 2 million to 50 billion, and particularly preferably 100 million to 10 billion.

[0058] In view of its high effect of activating intestinal cells, (D) lysine is contained in an amount of preferably 0.1 to 100,000 mass%, more preferably 1 to 10,000 mass%, and even more preferably 10 to 1,000 mass%, of (C) cellulose.

[0059] In view of the high effect of activating intestinal cells, the (A) Senna plant is contained in an amount of preferably 0.01 to 90 mass% of the total amount of the (A) Senna plant, (C) cellulose, and (D) lysine, more preferably 0.1 to 80 mass%, and even more preferably 1 to 70 mass%.

[0060] In view of its high effect of activating intestinal cells, the (A) Senna plant is contained in an amount of preferably 0.01 to 90 mass% of the total amount of the (A) Senna plant, (B) specific bacterium, (C) cellulose, and (D) lysine, more preferably 0.1 to 80 mass%, and even more preferably 1 to 70 mass%.

[0061] In view of the high effect of activating intestinal cells, the (B) specific bacterium is contained in an amount of preferably 0.01 to 90 mass% of the total amount of the (A) Senna plant, (C) cellulose, and (D) lysine, more preferably 0.1 to 50 mass%, and even more preferably 1 to 25 mass%.

[0062] In view of the high effect of activating intestinal cells, the (B) specific bacterium is contained in an amount of preferably 0.01 to 90 mass% of the total amount of the (A) Senna plant, the (B) specific bacterium, the (C) cellulose, and the (D) lysine, more preferably 0.1 to 50 mass%, and even more preferably 1 to 25 mass%.

[0063] In view of the high effect of activating intestinal cells, the (B) specific bacteria is preferably contained in an amount of 10,000 to 1 trillion bacteria per gram of the total amount of (A) Senna plant, (C) cellulose, and (D) lysine, more preferably 1 million to 100 billion bacteria, and particularly preferably 100 million to 10 billion bacteria.

[0064] In view of its high effect of activating intestinal cells, (C) cellulose is contained in an amount of preferably 0.01 to 90 mass% of the total amount of (A) Senna plant, (C) cellulose, and (D) lysine, more preferably 0.1 to 60 mass%, and even more preferably 1 to 40 mass%.

[0065] In view of its high effect of activating intestinal cells, (C) cellulose is contained in an amount of preferably 0.01 to 90 mass% of the total amount of (A) the Senna plant, (B) the specific bacterium, (C) cellulose, and (D) lysine, more preferably 0.1 to 60 mass%, and even more preferably 1 to 40 mass%.

[0066] In view of its high effect of activating intestinal cells, (D) lysine is contained in an amount of preferably 0.01 to 90 mass% of the total amount of (A) Senna plant, (C) cellulose, and (D) lysine, more preferably 0.1 to 60 mass%, and even more preferably 1 to 40 mass%.

[0067] In view of its high effect of activating intestinal cells, (D) lysine is contained in an amount of preferably 0.01 to 90 mass% of the total amount of (A) the Senna plant, (B) the specific bacterium, (C) cellulose, and (D) lysine, more preferably 0.1 to 60 mass%, and even more preferably 1 to 40 mass%.

[0068] In the oral composition of the present invention, there is no particular lower limit to the total amount of (A) the Senna plant, (C) cellulose, and (D) lysine. However, in view of the high effect of activating intestinal cells, the total amount is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, even more preferably 1% by mass or more, and particularly preferably 10% by mass or more, of the solid content.

[0069] In the oral composition of the present invention, there is no particular lower limit to the total amount of (A) the Senna plant, (B) the specific bacterium, (C) cellulose, and (D) lysine. However, in terms of the high effect of activating intestinal cells, the total amount is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, even more preferably 1% by mass or more, and particularly preferably 10% by mass or more, of the solid content.

[0070] In the oral composition of the present invention, there is no particular upper limit to the total amount of (A) the Senna plant, (C) cellulose, and (D) lysine, and it may be 100% by mass. However, from the viewpoint of ease of formulation, the total amount is preferably 95% by mass or less, more preferably 90% by mass or less, and even more preferably 85% by mass or less in the composition. In the oral composition of the present invention, the upper limit of the total amount of (A) the Senna plant, (B) the specific bacterium, (C) cellulose, and (D) lysine is not particularly limited and may be 100% by mass. However, from the viewpoint of ease of formulation, the total amount of these ingredients in the composition is preferably 95% by mass or less, more preferably 90% by mass or less, and even more preferably 85% by mass or less.

[0071] In the present invention, the total intake of (A) Senna plant, (B) specific bacteria, (C) cellulose and (D) lysine is preferably 4mg or more, more preferably 20mg or more, and even more preferably 40mg or more per day for an adult, in order to enjoy the effect more effectively.The upper limit is, for example, preferably 40000mg, more preferably 20000mg, and particularly preferably 8000mg.

[0072] The agent of the present invention may contain other commonly used ingredients in addition to (A) Senna plants, (B) specific bacteria, (C) cellulose, and (D) lysine, within the range that does not impair the effects of the present invention. When taken orally, such ingredients include water, excipients and binders other than cellulose, gloss agents, lubricants, stabilizers, diluents, bulking agents, thickeners, emulsifiers, antioxidants, pH adjusters, colorants, flavorings, additives, etc. The content of other ingredients can be appropriately selected depending on the form of the agent of the present invention.

[0073] Examples of the form of the oral composition include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, pills, pastes, creams, caplets, gels, chewables, and sticks. Among these, tablets, capsules, powders, granules, and liquids are preferred, and they are easy to deliver bacteria to the intestines and have the advantage of being easy to take, and the effects of the present invention are particularly excellent. Tablets are particularly preferred. Examples of oral compositions used as tablets, capsules, powders, granules, and liquids include supplements, food additives, container-packed beverages filled in PET bottles, cans, bottles, etc., and powdered beverages to be dissolved in water (hot water), milk, fruit juice, etc., and consumed.

[0074] Specific examples of oral compositions include foods as compositions for consumption. Foods include tea bags, various foods such as bread, confectionery, and noodles, and cooked foods. Examples of bread and confectionery include breads such as white bread, sweet bread, French bread, English bread, muffins, steamed bread, donuts, and waffles, cakes such as butter cake, sponge cake, chiffon cake, and hot cakes, frozen desserts such as chocolate, sherbet, and ice cream, jellies, and cookies. Examples of noodles include udon and somen. Examples of cooked foods include soups such as curry, stew, miso soup, and vegetable soup, as well as their bases and seasonings.

[0075] Specific examples of the use of the oral composition of the present invention include so-called health foods such as medicines (including quasi-drugs), general foods, nutritional functional foods, foods for specified health uses whose efficacy has been approved by a designated organization, and foods with functional claims. Foods with efficacy claims are sometimes collectively referred to as "functional foods."

[0076] As described in the Examples below, the oral composition of the present invention can activate intestinal epithelial cells. This adjusts the intestinal immunity, leading to intestinal regulation and activation of the intestinal immunity. In addition, it is expected to prevent and improve pathologies such as inflammation and glucose intolerance caused by obesity, so it can be expected to have a diet effect.

[0077] The oral composition of the present invention can also be used as a composition for regulating the intestines, a composition for improving immunity, and a dietary composition.

[0078] When the oral composition of the present invention is used as a composition for intestinal regulation, a composition for immune improvement, or a dietary composition, it is sufficient that the product can be distinguished from other products in terms of its use for intestinal regulation, immune improvement, and dietary purposes. For example, the intestinal regulation composition, immune improvement composition, and dietary composition of the present invention includes a product that indicates that the product has a function related to intestinal regulation, immune improvement, and dietary purposes on the main body, packaging, instructions, or advertising material (advertising medium) of the product of the present invention. The intestinal regulation composition, immune improvement composition, and dietary composition of the present invention are not limited to those that display (A) Senna plants, (B) specific bacteria, (C) cellulose, and (D) lysine as active ingredients on the product packaging, etc. For example, the active ingredients may not be specified. In addition, even if it is a general food product, those that are manufactured and sold with the suggestion of the use of intestinal regulation, immune improvement, and dietary purposes are included in the scope of the anti-obesity composition of the present invention.

[0079] Specifically, examples of compositions for intestinal regulation include those that are labeled with claims such as "activates intestinal cells (of the large intestine, etc.)", "activates intestinal cells (of the large intestine, etc.)", "activates the intestines", "improves the intestinal environment", "useful for improving the intestinal environment", "helps to improve the intestinal environment", "useful for improving intestinal flora", "improves bowel movements", "improves constipation", "improves bowel movements", "supports refreshing", "for those prone to constipation", etc.

[0080] Examples of immune-improving compositions include those labeled with expressions such as "maintains normal immune function", "helps in maintaining normal immune function", "enhances the body's barrier function", "helps in enhancing the body's barrier function", "helps in enhancing the body's barrier function", "maintains the body's barrier function", "enhances intestinal barrier function", "helps in enhancing intestinal barrier function", "helps in enhancing intestinal barrier function", "maintains intestinal barrier function", "helps in maintaining intestinal ...helps in enhancing intestinal barrier function", "enhances intestinal barrier function", "helps in enhancing intestinal barrier function", "maintains intestinal barrier function", "helps in maintaining intestinal barrier function", "helps in maintaining intestinal barrier function", "boosts immunity", and the like.

[0081] Examples of diet compositions include those labeled with claims such as "diet," "supports figure," "promotes metabolism," "for those concerned about body fat," "for those who are slightly obese," "for those concerned about weight (BMI)," "reduces weight and abdominal fat (visceral fat and subcutaneous fat)," and "reduces waist circumference."

[0082] The agent of the present invention may be appropriately designed so that the daily intake of (A) Senna plant, (B) specific bacteria, (C) cellulose, and (D) lysine is the above-mentioned intake amount, and may be in a form in which the above-mentioned intake amount is taken in one dose, or in a form in which the above-mentioned intake amount is taken in several doses. That is, for example, it can be stored in one container or in 2 to 4 multiple containers as a daily amount.

[0083] The agent of the present invention is preferably applied to mammals such as humans, and particularly preferably to humans. By applying to humans, the agent of the present invention is expected to have an effect of activating intestinal cells such as the large intestine, particularly an effect of activating intestinal epithelial cells, in the human intestine, and is expected to regulate intestinal immunity, enhance intestinal barrier function, improve intestinal environment, and lead to activation of intestinal immunity. In addition, it is expected to prevent and improve pathologies such as inflammation and glucose intolerance caused by obesity, and further to prevent infectious diseases such as digestive infections and respiratory infections.

[0084] The present invention provides a method for activating intestinal cells of an individual, comprising a step of orally ingesting (A) a Senna plant and (B) a specific bacterium, and, if necessary, (C) cellulose and (D) lysine to the individual. In the present invention, by activating the intestinal cells of the individual, it is expected that the effect of activating intestinal epithelial cells can be expected, which is expected to lead to the regulation of intestinal immunity, the improvement of intestinal environment, the enhancement of intestinal barrier function, and the activation of intestinal immunity. The individual is preferably a mammal such as a human, a cat, or a dog, and more preferably a human. In these methods, it is preferable to ingest (A) a Senna plant and (B) a specific bacterium, and, if necessary, (C) cellulose and (D) lysine for two or more consecutive weeks, more preferably to ingest (A) a Senna plant and (B) a specific bacterium, and, if necessary, (C) cellulose and (D) lysine for three or more consecutive weeks, and even more preferably to ingest (A) a Senna plant and (B) a specific bacterium, and, if necessary, (C) cellulose and (D) lysine for four or more consecutive weeks. When (A) a Senna plant and (B) a specific bacterium, and if necessary (C) cellulose and (D) lysine are ingested for two or more consecutive weeks, the subjects may ingest them every day or on some days, and may ingest them on two or more days per week, although ingesting them on three or more days per week is more preferable. EXAMPLES

[0085] The present invention will be described below based on examples, but the present invention is not limited to the following examples.

[0086] The following test substances were used. All of them were commercially available. (A) Senna plant Senna: Senna stem hydroethanolic extract powder (extract powder) was used. Candle bush: A powder (ground powder) made by drying and crushing candle bush leaves was used. (B) Specific bacteria Bacillus genus: Bacillus coagulans powder is used. Each gram contains 5 billion live Bacillus coagulans bacteria. Enterococcus genus: Enterococcus faecalis powder is used. Each gram contains 5 billion live Enterococcus faecalis bacteria. Clostridium genus: Clostridium butyricum powder is used. Each gram contains 100 million live Clostridium butyricum bacteria. (C) Cellulose: Powdered cellulose having an average particle size of 45 μm was used. (D) Lysine: L-lysine hydrochloride was used. Comparative example: Bifidobacterium genus: A mixture of Bifidobacterium lactis and maltodextrin was used. Each gram contained 100 million live Bifidobacterium lactis bacteria.

[0087] (Test Method) (1)Cell culture (1-1) Cell Human colon cancer-derived cells (Caco-2) were used as a model cell for human intestinal epithelium.

[0088] (1-2)Culture In a 37℃, 5% CO2 incubator, 75 cm 2Caco-2 cells were cultured in flasks using a medium made of DMEM supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino acids, and 1% penicillin-streptomycin (hereinafter referred to as the "culture medium").

[0089] (1-3) Preculture The cells were suspended by trypsinization and then transferred to a 75 cm 2 From flask to 96-well plate: 5.0 x 10 3 100 μL of cells were seeded at a cell density of 10 cells / well. The cells were pre-cultured for 24 hours in a 5% CO2 incubator at 37°C.

[0090] (2) Caco-2 cell proliferation test After removing the medium, 100 μL / well of medium containing the test substance was added, and the cells were cultured in a 37° C., 5% CO 2 incubator for 24 hours. The test substances used were the compositions of Comparative Examples 1 to 8 and Examples 1 to 6, each having the composition shown in Table 1 below. The test substance-containing medium was prepared so that the total concentration of each component of the composition in the culture medium was 100 μg / mL. As a control, a culture medium containing no test substance was added.

[0091] [Table 1]

[0092] After the incubation, the medium was removed and each well was washed once with 200 μL of PBS, and then 150 μL of Cell Counting Kit-8 (Dojindo Chemical Industries, Ltd.) diluted 30 times with serum-free DMEM was added to each well. The wells were left to stand in a 37°C, 5% CO2 incubator to allow for adequate color development, and the absorbance at 450 nm was measured.

[0093] Additionally, Cell Counting-8 Kit diluted 30-fold by volume with serum-free DMEM was placed in an empty well (for background), and similarly incubated and absorbance was measured.

[0094] A plate reader (SpectraMax i3x, Molecular Devices) was used to measure absorbance, and the % of control (relative number of live cells with the number of live cells in the control taken as 100%) was calculated based on the data obtained to evaluate the cell activation activity for each Example and Comparative Example. The results are shown in Figure 1. The absorbance ratio and the Caco-2 cell number ratio are directly proportional to each other, so the absorbance ratio indicates the Caco-2 cell number ratio. % of control=(Data sample-Data blank) / (Data control-Data blank)×100

[0095] (Test Results) 1, in Examples 1 to 6, the ratio of the number of Caco-2 cells was increased compared to Comparative Examples 1 to 8. When considering Examples 1 to 6 in FIG. 1, it is found that Example 4, which combines (A) a Senna plant and (B) a specific bacterium with (C) cellulose, is highly effective, and a comparison between Examples 4 and 5 shows that the effect is enhanced by combining bacteria from three genera. In particular, a comparison between Examples 5 and 6 shows that an excellent effect can be obtained by combining the four components (A) to (D). While the total amount of the sample added in the Examples and Comparative Examples is the same, the cell activation activity of the Comparative Examples is not usually greater within the range of additive effects. However, the cell activation activity of each Example is clearly higher than that of the Comparative Examples, and it is clear that this is a synergistic effect.

[0096] From the above results, the oral composition of the present invention exhibits an excellent intestinal epithelial cell activating effect as an intestinal cell activating action, and is therefore expected to have an intestinal regulation effect, an immune improving effect, and a diet effect.

[0097] A manufacturing example of the oral composition of the present invention is shown below. In the following, the (A) senna extract powder was the same as the "senna" used in the above Examples 1 to 6. The (A) candle bush crushed powder was the same as the "candle bush" used in the above Examples 1 to 6. The (B) Bacillus coagulans, (B) Enterococcus faecalis, (B) Clostridium butyricum, and (D) powdered cellulose were the same as the "Bacillus genus bacteria," "Enterococcus genus bacteria," "Clostridium genus bacteria," and "cellulose" used in the above Examples.

[0098] [tablet] Tablets were manufactured according to the composition shown in Table 2. Each tablet was manufactured with a weight of 300 mg. The resulting tablets can be taken 1 to 4 per day with 100 ml of water. All tablets are effective for intestinal regulation, immune improvement, and dieting.

[0099] [Table 2]

[0100] [Granules] Granules were manufactured according to the composition in Table 3. The obtained granules can be taken at a dose of 3 g per day by dissolving in 100 ml of water. All granules are effective for intestinal regulation, immune improvement, and dieting.

[0101] [Table 3]

[0102] [Hard capsule] Hard capsules were produced by encapsulating the ingredients in the composition shown in Table 4 with a coating containing gelatin or hydroxypropyl cellulose. Each hard capsule was produced at 400 mg. One to two capsules per day can be taken with 100 ml of water. All hard capsules were easy to manufacture and had an excellent swallowing sensation. All hard capsules are also effective for intestinal regulation, immune improvement, and dieting.

[0103] [Table 4] [Industrial Applicability]

[0104] The composition of the present invention has an intestinal cell activating effect and can be used as a health food or the like, and is therefore industrially useful.

Claims

1. An oral composition comprising the following (A) and (B): (A) Senna plants (B) one or more bacteria selected from the genus Bacillus, the genus Enterococcus, and the genus Clostridium

2. An oral composition comprising the following (A), (B) and (C): (A) Senna plants (B) one or more bacteria selected from the genus Bacillus, the genus Enterococcus, and the genus Clostridium (C) Cellulose

3. An oral composition comprising the following (A), (B), (C) and (D): (A) Senna plants (B) one or more bacteria selected from the genus Bacillus, the genus Enterococcus, and the genus Clostridium (C) Cellulose (D) Lysine

Citation Information

Patent Citations

  • Constipation improving agent

    JP2012158561A